Brief: Ose Immunotherapeutics Posts FY Operating Loss Of 23.0 Million Euros

Ose Immunotherapeutics SA

27/03/2024 17:13

March 27 (Reuters) - OSE Immunotherapeutics SA  OSE.PA :
    * OSE IMMUNOTHERAPEUTICS REPORTS FULL YEAR 2023 FINANCIAL
RESULTS
AND PROVIDES BUSINESS STRATEGY UPDATE
    * FY CONSOLIDATED OPERATING LOSS EUR -23.0 MILLION
    * AS OF DECEMBER 31, 2023, AVAILABLE CASH TOTALED EUR 18.7
MILLION, VERSUS EUR 25.6 MILLION YEAR AGO
    * FY CURRENT OPERATING EXPENSES WERE €25.2 MILLION (VERSUS
€36.6
MILLION IN 2022) OF WHICH 74% RELATED TO RESEARCH AND
DEVELOPMENT

Source text for WorkSpace:  urn:newsml:reuters.com:*:nGNE5y0lVx
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))